Author

M. Daga

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 4 Approach:experimental assay· 4 Organism:human· 4 Assay:proteomics· 4 Research Focus:cell-cell communication· 2 Research Focus:clustering· 2 Research Focus:differential expression· 2 Research Focus:host-pathogen & immune response· 2

Frequent Co-Authors

A. Cho· 3 shared A. Gazumyan· 3 shared C. Gaebler· 3 shared D. Schaefer-Babajew· 3 shared E. Bednarski· 3 shared F. Muecksch· 3 shared F. Schmidt· 3 shared M. Caskey· 3 shared

Activity by Year

2021-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

A. Cho

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Spatial characterization of interface dermatitis in cutaneous lupus reveals novel chemokine ligand-receptor pairs that drive disease

S. Shakiba, N.-S. Haddadi, K. Afshari, J. E. Lubov, H. S. Raef, R. Li, U. Yildiz-Altay, M. Daga, M. A. Refat, E. Kim, J. Galindo de Laflin, A. Akabane, P. Romano, J. Vongvirath, S. Sherman, , J. M. Richmond

This study identifies novel chemokine ligand-receptor pairs involved in immune cell recruitment in cutaneous lupus by combining spatial transcriptomics, proteomics, and immunological assays.

bioRxiv · Jan 5, 2024Immunology

Increased Potency and Breadth of SARS-CoV-2 Neutralizing Antibodies After a Third mRNA Vaccine Dose

F. Muecksch, Z. Wang, A. Cho, C. Gaebler, T. Ben Tanfous, J. DaSilva, E. Bednarski, V. Ramos, S. Zong, B. Johnson, R. Raspe, D. Schaefer-Babajew, I. Shimeliovich, M. Daga, K.-H. Yao, , M. Nussenzweig

This study shows that a third mRNA vaccine dose increases the potency and breadth of SARS-CoV-2 neutralizing antibodies, particularly against the Omicron variant, through the expansion and evolution of memory B cells.

bioRxiv · Feb 14, 2022 · PreprintImmunology

Anti- SARS-CoV-2 Receptor Binding Domain Antibody Evolution after mRNA Vaccination

A. Cho, F. Muecksch, D. Schaefer-Babajew, Z. Wang, S. Finkin, C. Gaebler, V. Ramos, M. Cipolla, P. Mendoza, M. Agudelo, E. Bednarski, J. DaSilva, I. Shimeliovich, J. Dizon, M. Daga, , M. C. Nussenzweig

This study examines memory B cell evolution 5 months after mRNA vaccination in naive individuals, finding increased neutralizing activity but no further breadth or potency, and higher overall plasma neutralizing potency compared to natural infection.

bioRxiv · Jul 29, 2021Immunology

Naturally enhanced neutralizing breadth to SARS-CoV-2 after one year

Z. Wang, F. Muecksch, D. Schaefer-Babajew, S. Finkin, C. Viant, C. Gaebler, H.- H. Hoffmann, C. O. Barnes, M. Cipolla, V. Ramos, T. Y. Oliveira, A. Cho, F. Schmidt, J. D. Silva, E. Bednarski, , M. C. Nussenzweig

This study shows that convalescent individuals with or without vaccination maintain neutralizing activity and memory B cells against SARS-CoV-2 for up to one year, with vaccination enhancing breadth and potency against variants.

bioRxiv · May 7, 2021Immunology